Abstract-Obesity is associated with vascular endothelial dysfunction, as indicated by impaired endothelium-dependent dilation. Presently there is no direct evidence that energy intake-restricted weight loss alone improves conduit or resistance artery endothelium-dependent dilation, the mechanisms involved, or whether improvements differ with patient age. A total of 40 overweight or obese (body mass index: Ն25Ͻ40 kg/m 2 ) nondiabetic men and women aged 21 to 69 years completed 12 weeks of reduced energy intake (nϭ26; 15 male) or attention control (nϭ14; 9 male) and 4 weeks of weight maintenance (randomized trial). Energy intake restriction reduced estimated total energy intake (33%), body weight (10.5%), total and abdominal body fat, plasma leptin, oxidized low-density lipoprotein, and improved several metabolic risk factors. Brachial artery flow-mediated dilation was increased by 30% (6.0Ϯ0.7% versus 7.9Ϯ0.7%⌬; Pϭ0.01; nϭ17). Peak forearm blood flow during intrabrachial artery infusion of acetylcholine was increased by 26% (16.8Ϯ1.4 versus 21.1Ϯ1.9 mL/100 mL per minute; PϽ0.05; nϭ15); this was inversely related to the reduction in the abdominal visceral:subcutaneous fat ratio (rϭϪ0.46; PϽ0.05) and was abolished by inhibition of NO synthesis with N G -monomethyl-L-arginine. Improvements in endothelium-dependent dilation were not related to age: mean increases in subjects Ͼ50 years of age were similar to or greater than those Ͻ50 years of age. Energy intake-restricted weight loss alone is an effective intervention for improving peripheral conduit and resistance artery endothelial function in young and older overweight/obese adults. The improvements in resistance artery function are mediated by an increase in NO bioavailability and are related to reductions in abdominal visceral fat. Key Words: endothelium Ⅲ obesity Ⅲ intra-abdominal fat Ⅲ nitric oxide Ⅲ energy intake Ⅲ adipokines Ⅲ aging O besity is associated with increased risk of cardiovascular diseases (CVDs), believed attributable in part to vascular endothelial dysfunction, as indicated by impaired endothelium-dependent dilation (EDD). 1,2 Thus, interventions that improve EDD in overweight and obese adults may have important clinical implications for the prevention of CVD.
O besity is associated with increased risk of cardiovascular diseases (CVDs), believed attributable in part to vascular endothelial dysfunction, as indicated by impaired endothelium-dependent dilation (EDD). 1, 2 Thus, interventions that improve EDD in overweight and obese adults may have important clinical implications for the prevention of CVD.
As reviewed recently, 3 surgical treatment, short-term verylow calorie diets, and multicomponent lifestyle interventions that include aerobic exercise and weight loss generally lead to improvements in EDD, particularly in overweight/obese adults with comorbidities. However, presently there is no evidence that moderate energy intake restriction-based weight loss alone improves EDD in otherwise healthy overweight/obese adults, 3 and no randomized trial with a nonweight loss control has been conducted on this question. This is important in that many overweight or obese adults who have not yet developed other clinical disorders are not candidates for gastric-bypass surgery, cannot sustain diets involving severe caloric restriction, and/or will not exercise regularly.
If energy intake restriction-induced weight loss does increase EDD in this group, one key question is whether improvements are observed in both brachial artery flowmediated dilation (FMD), a measure of peripheral conduit artery EDD, and the increase in forearm blood flow in response to intrabrachial artery infusion of acetylcholine, a measure of peripheral resistance vessel EDD. Both of these expressions of EDD are predictors of future CV events, 4 -7 and it has been suggested that use of one or the other measure has contributed to inconsistent findings in previous studies of weight loss on EDD. 3, 8 Another important question concerns the mechanisms involved. Generally, improvements in EDD with weight loss have not been related to reductions in body mass or total body fat. 3,8 -11 However, endothelial dysfunction in human obesity may be more strongly related to body fat distribution, particularly abdominal visceral fat, than to total fat mass. 12, 13 Circulating proinflammatory adipokines/acute-phase reac-tants, oxidative stress, and certain neurohumoral factors have been linked with increased abdominal visceral fat as possible intermediary mechanisms contributing directly or indirectly to impaired EDD in overweight/obese adults. 1 Moreover, impaired EDD in overweight/obese humans is associated with reduced NO bioavailability. 1, 14 Presently, it is unknown whether improvements in EDD with energy intake restriction-based weight loss are related to reductions in abdominal visceral fat or mediated by increased NO bioavailability.
Finally, the risk of CVD increases progressively with age. 15 As a result, it is important to establish the efficacy of interventions in adults varying in age. However, currently there is no information regarding the effects of energy intake-restricted weight loss alone on EDD in adults Ͼ50 years of age.
We hypothesized that energy intake restriction-based weight loss alone would improve EDD in both peripheral conduit and resistance arteries in otherwise healthy overweight and obese adults and that these improvements would be related to reductions in abdominal visceral fat and changes in circulating adipokines and selective neurohormonal factors. We further hypothesized that middle-aged and older adults would demonstrate improvements in EDD as great or greater than those observed in young adults.
To address these issues, we conducted a randomized, controlled intervention trial in which brachial artery FMD was measured before and at the end of energy intake restriction-induced weight loss alone or attention control (parallel group design) in overweight and obese adults varying in age who were free of clinical disease. Forearm blood flow responses to intrabrachial artery infusion of acetylcholine, with and without inhibition of NO production, were determined in a subgroup of the subjects who underwent weight loss. Body composition was assessed by dual x-ray absorptiometry, and abdominal fat was determined by computed tomography in all of the subjects.
Methods

Subjects
A total of 56 overweight and obese (body mass index: Ն25Ͻ40 kg/m 2 ) men (nϭ29) and women (nϭ27) aged 21 to 69 years were enrolled. Subjects were nonsmokers, nondiabetic, and were free of clinical diseases as assessed by medical history, physical examination, blood chemistry, and resting and exercise ECG (men Ͼ40 and women Ͼ50 years old only). All of the subjects self-reported that they were weight stable (Ϯ2 kg) for the previous 6 months. Sixteen subjects, primarily from the attention control group, dropped out after random assignment because of lack of time or interest in serving as a control, issues related to arterial catheterization, or noncompliance with treatment. A total of 40 subjects completed the weight loss (nϭ26) or attention control (nϭ14) treatments. All of the procedures were approved by the human research committee of the University of Colorado at Boulder. The nature, benefits, and risks of the study were explained to the volunteers, and their written informed consent was obtained before participation.
Measurements
All of the measurements were performed at the University of Colorado at Boulder General Clinical Research Center (GCRC) after an overnight fast and 24-hour abstention from alcohol and physical activity. Details on measurements of subject characteristics, body composition, humoral factors, and diet composition and physical activity are in the online data supplement (available at http://hyper.ahajournals.org).
EDD and Endothelium-Independent Dilation
EDD and endothelium-independent dilation (EID) of the brachial conduit artery were performed as described previously by our laboratory. 16 -20 Details are in the online data supplement.
Complete before and after data were obtained on 17 (11 men and 6 women) and 11 (7 men and 4 women) subjects in the weight loss and attention control conditions, respectively: data from 12 subjects were lost because of electronic file corruption (nϭ6) or poor quality ultrasound images in the pretreatment and/or posttreatment measurements (nϭ6). All of the FMD analysis was performed and analyzed by the same investigator (G.L.P.), who was blinded to treatment condition.
Forearm resistance vessel EDD and endothelium-independent dilation were determined as described previously by our laboratory. 21 Details are in the online Data Supplement. Complete before and after data were obtained on 15 (9 men and 6 women) subjects in the weight loss condition group because of issues related to arterial catheterization (nϭ5) or poor quality forearm blood flows during infusion (nϭ6). All of the analyses were performed by the same investigator (A.J.D.), who was blinded to treatment condition.
Energy Intake Restriction and Attention Control Treatments
After completion of baseline measurements, subjects were randomly assigned to either energy intake restriction weight loss or attention control treatments. Subjects assigned to the weight loss intervention received counseling and consumed an individualized research diet prepared by a GCRC bionutritionist designed to reduce their caloric intake to meet a goal of 10% weight loss within 12 weeks. 22 The diet ensured that total caloric intake was not Ͻ1200 kcal per day, to maintain vitamin and mineral adequacy. 23 Subjects gradually substituted the GCRC food with self-prepared meals. To isolate the effects of weight loss from energy intake restriction, subjects remained weight stable (Ϯ2 kg) for 4 weeks before the end-treatment measurements were performed. During the entire treatment period, weight loss subjects reported to the GCRC every week to have their body weight assessed and to meet with a GCRC bionutritionist to ensure compliance to the diet. Subjects assigned to the attention control condition underwent the same testing every 2 weeks and other interactions with the study staff but maintained their baseline diet. These subjects were offered the resources for a weight loss program after completion of the study.
Data Analysis
All of the data are presented as meansϮSEs. Details on statistical analysis are in the online data supplement.
Results
Subject Characteristics, Body Composition, Humoral Factors, Energy Intake, and Physical Activity
Baseline and end-treatment values for the weight loss and attention control groups are shown in Tables 1 to 3 and Table  S1 . At baseline, the weight loss group was slightly older (PϽ0.05) and had a higher body weight (PϽ0.05), but there were no other group differences.
Weight loss resulted in reductions in fasting plasma total cholesterol, insulin, and the homeostasis model assessment of insulin resistance (PϽ0.05). There were trends for improvements in plasma low-density lipoprotein cholesterol (Pϭ0.08) and systolic blood pressure (Pϭ0.05), but diastolic blood pressure, plasma high-density lipoprotein cholesterol, total:high-density lipoprotein cholesterol ratio, triglycerides, very-low density lipoprotein cholesterol, fasting glucose, insulin sensitivity, and glucose sensitivity were not significantly changed (Table 1) . Body weight decreased by 10.4% and total body fat (percentage and kilograms), fat-free mass, total abdominal fat, visceral fat, and subcutaneous fat were reduced (PϽ0.05; Table 2 ). The abdominal visceral:subcutaneous fat ratio and waist:hip ratio were unchanged. Plasma oxidized low-density lipoprotein and leptin were reduced (PϽ0.05), whereas plasma C-reactive protein, interleukin-6, tumor necrosis factor-␣, total antioxidant status, adiponectin, norepinephrine, cortisol, endothelin-1, aldosterone, and free fatty acids were not significantly changed (Table 3) . Estimated total energy, fat, carbohydrate, and protein intake were reduced (PϽ0.05), but there was no change in estimated physical activity (Table S1 ). In the attention control group, all of the variables were unchanged at end treatment compared with baseline (Tables 1 to 3 and Table S1 ).
Peripheral Conduit Artery FMD and EID
At baseline, brachial artery diameter (Table S2 ) and brachial artery FMD and EID ( Figure 1) were not different in the weight loss and attention control groups. In the overall group, baseline FMD was inversely related to serum triglycerides (rϭϪ0.34; PϽ0.05) and very low-density lipoprotein (rϭϪ0.34; PϽ0.05).
Baseline brachial artery diameter was not different before and after weight loss (Table S2 ). Weight loss resulted in an Ϸ30% mean increase in FMD but no change in EID ( Figure  1 ). Among individuals, the percentage of change in FMD from baseline to end treatment in the weight loss group was inversely related to changes in plasma norepinephrine concentrations (rϭϪ0.43; PϽ0.05; Figure 2 ). Changes in FMD were not related to changes in any other variable (all PϾ0.05), including subject age (rϭ0.21; PϾ0.05). Brachial artery FMD increased with weight loss in subjects Ͻ50 (ϩ28%: 6.0Ϯ1.4% versus 7.7Ϯ0.9%; PϽ0.05; nϭ8), as well as Ն50 (ϩ31%: 6.1Ϯ0.6% versus 8.0Ϯ1.0%; PϽ0.05; nϭ9) years of age. In the attention control group, brachial artery diameter (Table S2) , FMD, and EID were unchanged at end treatment compared with baseline ( Figure 1 ).
Peripheral Resistance Vessel EDD and EID
At baseline, peak forearm blood flow in response to acetylcholine was inversely related to fasting plasma insulin (rϭϪ0.53) and homeostasis model assessment of insulin resistance (rϭϪ0.51) (both PϽ0.05). Weight loss resulted in an increase in the forearm blood flow response to acetylcholine (peak: ϩ26%) but not to sodium nitroprusside (Figure 3 ). The change in the peak forearm blood flow response to acetylcholine was inversely related to changes in abdominal visceral fat (rϭϪ0.43; Pϭ0.05) and the abdominal visceral: subcutaneous fat ratio (rϭϪ0.46; PϽ0.05; Figure  4) , and was positively related to changes in plasma leptin (rϭ0.48) and aldosterone (rϭ0.61) concentrations (both PϽ0.05) but was not related to subject age (rϭ0.20; PϾ0.05). The increases in the forearm blood flow response to acetylcholine with weight loss were significant in subjects Ն50 years of age (ϩ38%: peak FBF: 16.8Ϯ2.0 versus 23.1Ϯ2.9 mL/100 mL of forearm volume per minute; PϽ0.05; nϭ9) but not in the smaller subgroup of subjects Ͻ50 years of age (ϩ9%: peak FBF: 16.6Ϯ2.0 versus 18.1Ϯ3.7 mL/100 mL of forearm volume per minute; Pϭ0.34; nϭ6).
In contrast to the greater forearm blood flow response to acetylcholine administration alone after compared with before weight loss, the increase in forearm blood flow to acetylcholine was similar before and after weight loss when NO synthesis was inhibited by coadministration of N G -monomethyl-L-arginine ( Figure 3) . This was the case because inhibition of NO production had a greater suppressive effect on the forearm blood flow response to acetylcholine after compared with before weight loss, suggesting that the greater response to acetylcholine after weight loss was mediated by enhanced NO bioavailability.
Relations Between Peripheral Conduit Artery and Resistance Vessel EDD
Measurements of brachial artery FMD and increases in forearm blood flow to acetylcholine were available in 15 overall subjects at baseline and in 9 subjects before and after weight loss. The 2 measures of EDD were not related at baseline (rϭ0.14; Pϭ0.30), nor were the changes with weight loss related (rϭ0.30; Pϭ0.22).
Discussion
The primary new finding of this study was that moderate energy intake restriction-based weight loss alone (ie, in the absence of other lifestyle or pharmacological interventions) can improve EDD in overweight and obese men and women without CVD or other major risk factors for CVD. Endothelium-independent dilation was unaffected by weight loss, demonstrating that the effects of the intervention were specific for the vascular endothelium. Previous studies have shown that weight loss produced by a combination of moderate caloric restriction and aerobic exercise can increase EDD. 24, 25 However, regular exercise improves EDD independent of weight loss. 21 Thus, the present randomized, controlled trial is the first to demonstrate that a conventional weight loss program alone can improve EDD in otherwise healthy overweight and obese adults. Our findings of improved EDD differ from previous studies that found no changes with weight loss in nondiabetic premenopausal women with a history of gestational diabetes 11 or in overweight adults with hypertriglyceridemia. 26 The addition of the drug orlistat to facilitate energy intakerestricted weight loss has produced mixed results: one study found improvements in EDD related to reductions in plasma low-density lipoprotein cholesterol, 11 whereas another found no effect on EDD. 8 All of the studies produced significant weight loss, but there are many methodologic differences that could contribute to the inconsistent results.
A novel finding from our study was that improvements in EDD with weight loss were observed in both peripheral conduit arteries and resistance vessels. Previous investigations have measured only 1 of these expressions of EDD. This is important because both measures are independent predictors for future cardiovascular events. 4 -7,27 We found that the mean improvements in brachial artery FMD and the forearm blood flow responses to acetylcholine were similar (Ϸ25% to 30%) with weight loss. However, among the small group of subjects who had both measures, the improvements in conduit artery and resistance vessel EDD did not correlate, as was the case at baseline. These observations are consistent with previous findings that the 2 measures are not related 28, 29 and likely reflect distinct expressions of endothelium-mediated vasodilatory function. In the present study, the absence of significant relations between changes in EDD and body mass or total body fat with weight loss is in agreement with most previous reports. 3 A unique feature of the present investigation, however, was the measurement of abdominal fat and its distribution with computed tomography. We found that changes in brachial artery FMD with weight loss were not related to corresponding reductions in any measure of abdominal fat. In contrast, changes in the peak forearm blood flow response to acetylcholine were inversely related to changes in abdominal visceral fat and the abdominal visceral:subcutaneous fat ratio. The latter findings provide evidence that improvements in vascular endothelial function with weight loss may be linked to reductions in abdominal visceral fat. It is unclear why improvements in brachial FMD did not show such a relation. The facts that these are different functions and that the 2 samples did not include the same subjects may explain the differences. Alternatively, it is possible that improvements in peripheral resistance vessel EDD are selectively related to abdominal visceral fat.
Impaired forearm blood flow responses to acetylcholine in overweight/obese compared with normal weight adults are mediated at least in part by reduced NO bioavailability. 1, 14 In the present study, we found that the blood flow response to acetylcholine was improved after weight loss, but not during coinfusion with N G -monomethyl-L-arginine, which inhibits NO production by endothelial NO synthase. Thus, another novel finding of our investigation is that energy intake restriction-based weight loss alone improves peripheral resistance vessel EDD in otherwise healthy overweight and obese adults by increasing NO bioavailability. The mechanisms by which weight loss, per se, improved NO bioavailability are uncertain. Oxidative stress is thought to develop in human obesity, 13, 14, 30 and the resulting excess of reactive oxygen species can react with NO, reducing its bioavailability and impairing EDD. The fact that plasma oxidized low-density lipoprotein was lower after weight loss is consistent with the possibility of reduced oxidative stress, and this may have contributed to the increase in NO bioavailability and improved EDD.
We observed several expected changes in body composition and metabolic profile in response to our weight loss intervention. The reductions in body mass and total body fat were as great or greater than in previous studies on weight loss and EDD that did not involve gastric bypass surgery, 3 and the intervention also produced substantial reductions in regional adiposity, including total, subcutaneous, and visceral abdominal fat. Heart rate, plasma fasting total cholesterol, and insulin were reduced. Although glucose sensitivity was not improved in response to weight loss, fasting glucose was normal in our subjects at baseline and was maintained with less circulating insulin after weight loss, as indicated by Ϸ25% and 30% reductions in fasting insulin and homeostasis model assessment of insulin resistance score, respectively. Together, these changes, along with the Ϸ50% increase in insulin sensitivity observed, are consistent with an improvement in insulin sensitivity after weight loss. Thus, the intervention produced a marked improvement of several CVD risk factors in these overweight and obese adults.
However, other than abdominal visceral fat, none of these favorable changes in risk factors correlated with improvements in EDD, as generally observed in previous weight loss studies. 3, 8, 10, 26 Several changes in humoral factors with potential vascular effects also were noted with weight loss. Plasma leptin concentrations were decreased, as expected with the reduction in fat mass, and were positively related to changes in peak forearm blood flow with acetylcholine. A similar relation between changes in plasma leptin and brachial FMD with weight loss has been reported, 8 indicating that subjects with the greatest decrease in leptin had no change or a decrease in EDD. 8 Although mean plasma concentrations of aldosterone did not decrease with weight loss, a positive relation was found with the change in peak forearm blood flow among individual subjects. Given that these hormones exert NO-mediated vasodilatory effects, 31, 32 reductions could negate other beneficial influences of weight loss on EDD. We found no significant changes in circulating levels of several neural, hormonal, inflammatory, and local vasoconstrictor factors or in adiponectin. In contrast to some previous observations, 9, 26, 33, 34 but in agreement with others, 8, 35 plasma concentrations of C-reactive protein, interleukin-6, and tumor necrosis factor-␣ were not reduced after weight loss compared with attention control. However, among individuals, changes in plasma norepinephrine concentration with weight loss were inversely related to changes in brachial artery FMD, suggesting a possible link between reductions in sympathetic activity and peripheral conduit artery EDD.
Aging is associated with impaired vascular endothelial function [17] [18] [19] 21, 36, 37 and increased risk of CVD, independent of obesity. 15 As such, interventions that can improve endothelial function in overweight and obese middle-aged and older adults have important clinical implications for preventing age-associated CVD. In the present study, the improvements in EDD with weight loss were not related to subject age, and subjects Ն50 years of age showed improvements in both measures of EDD. To our knowledge, these are the first data concerning the effects of weight loss alone on EDD in overweight and obese adults differing in age, and they show that middle-aged and older adults respond as well or better to this intervention than young adults. 
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At least 2 important limitations should be emphasized. First, there was a high rate of dropout in the attention control group and incomplete data for our measures of EDD. Although the weight loss and attention control groups generally were similar at baseline and we were able to demonstrate improvements in EDD with weight loss, these factors could have biased our results. For example, it is possible that the weight loss subjects on whom we did not obtain interpretable measures of EDD would not have shown improvements, thus reducing the size or significance of the overall group increases in EDD. Second, the rate of weight loss in the present study (10% of baseline body weight over 3 months) is more aggressive than recommended by National Institutes of Health guidelines (decrease of 10% over a 6-month period). Therefore, individuals undergoing the present weight loss regimen should do so only under medical supervision.
Perspectives
The current study provides the first experimental support for the efficacy of energy intake restriction-induced weight loss alone for restoring vascular endothelial function in otherwise healthy overweight and obese adults. Our results indicate that weight loss improves both peripheral conduit artery and resistance vessel EDD, with the latter mediated by increases in NO bioavailability. The improvements in conduit artery FMD may be related to reductions in sympathetic activity, whereas increases in resistance vessel EDD are related to reductions in abdominal visceral fat. Importantly, middleaged and older overweight and obese adults demonstrate similar or greater improvements in EDD with weight loss as young adults. These findings have important clinical implications for the therapeutic role of conventional, moderate energy intake restriction-based weight loss programs to improve vascular endothelial function and perhaps contribute to the prevention of age-associated CVD in overweight and obese men and women.
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Supplemental Methods
Subject characteristics. Arterial blood pressure and heart rate were measured over the brachial artery during supine rest using a semi-automated device (Dynamap XL, Johnson and Johnson).
Total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoproteincholesterol (HDL-C), very low-density lipoprotein cholesterol (VLDL-C), triglycerides, glucose, and insulin were determined by the University of Colorado GCRC core laboratory using standard assays. The homeostasis model of insulin resistance (HOMA-IR) was calculated by the formula:
[fasting glucose (mg/dl) x fasting insulin μU/L)]/405.
1 A modified frequently sampled intravenous glucose tolerance test was performed to estimate insulin sensitivity (Si) and glucose function (Sg) using a minimal model approach.
2
Body Composition. Body mass index (BMI) was calculated from height and weight to the nearest 0.1 kg, and waist and hip circumference were measured by anthropometry. 3 Total body fat and fat-free mass were determined using dual energy x-ray absorptiometry (DPX-IQ, GE/Lunar, Inc.). 4 Total, visceral, and subcutaneous fat volumes in the abdominal region (at the level of L4-L5) were measured by computed tomography using commercially available software (Slice-O-Matic v4.2, Tomovision) by an investigator (SDB) blinded to treatment condition. with a linear array transducer was used to assess peripheral conduit artery EDD via measurement of brachial artery flow-mediated dilation (FMD) and endothelium-independent dilation via measurement of brachial artery dilation in response to sublingual nitroglycerin as previously described by our laboratory. [6] [7] [8] [9] [10] Responses are expressed as mm and % change from baseline diameter. Blood flow data could not be obtained because of technical limitations with the ultrasound machine, so estimation of the hyperemic stimulus was not possible.
Forearm resistance vessel EDD and endothelium-independent dilation were determined by strain-gauge venous occlusion plethysmography (Hokanson, Inc.) as the forearm blood flow responses to incremental intra-brachial artery infusion of acetylcholine (5 minutes each @ 8, 16, 32 μg/100 ml forearm volume/min) and sodium nitroprusside (5 minutes each @ 1, 2, 4 μg/100 ml forearm volume/min), respectively. 11 To assess the portion of EDD that was NO-mediated, N g -monomethyl L-arginine (L-NMMA), an inhibitor of NO synthesis by NO synthases, was infused for 5 min (5 mg/min) before and then continuously during incremental doses of acetylcholine.
Data
Analysis. An independent t-test was performed to determine baseline group differences. A 2x2 repeated measures analysis of variance (ANOVA) was performed to determine the effects of FMD (% change) 6.0 ± 0.7 7.9 ± 0.7* † 6.6 ± 0.8 6.6 ± 0.9
Supplemental Results
Values are mean ± standard error; *P<0.05 vs. Pre; †P<0.05 group (Weight loss, Control) x time (Pre, Post) interaction; FMD, flow-mediated dilation.
